New-onset post-transplant diabetes mellitus after haploidentical hematopoietic cell transplant with post-transplant cyclophosphamide.

Autor: Mangan BL; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA., Patel D; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Chen H; Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA., Gatwood KS; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA., Byrne MT; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Sengsayadeth S; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Goodman S; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Dholaria B; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Kassim AA; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Jagasia M; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Chinratanalab W; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA., Culos KA; Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA., Engelhardt BG; Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Jazyk: angličtina
Zdroj: EJHaem [EJHaem] 2020 Nov; Vol. 1 (2), pp. 576-580. Date of Electronic Publication: 2020 Sep 23.
DOI: 10.1002/jha2.70
Abstrakt: Haploidentical hematopoietic cell transplant (haplo-HCT) with post-transplant cyclophosphamide (PTCY) is utilized for patients with hematological disorders but without conventional donors. The effects of new-onset post-transplant diabetes mellitus (PTDM) following haplo-HCT are unknown. We examined PTDM incidence and outcomes after haplo-HCT with PTCY. Patients without diabetes receiving haplo-HCT (n=64) were analyzed for PTDM diagnosis (defined as blood glucose≥ 200 mg/dL). By day 100, 14 (22%) patients developed PTDM (median, 18 days). Hyperglycemia (blood glucose ≥ 200 mg/dL) preceded corticosteroids in 11 (79%) individuals. PTDM patients had increased death/relapse (p=0.029). PTDM occurs frequently, precedes corticosteroids, and leads to inferior outcomes following haplo-HCT. PTDM prophylaxis/treatment may improve HCT survival.
Competing Interests: Conflict of interest: The authors declare no conflict of interest.
Databáze: MEDLINE
Externí odkaz: